Pfizer gets ACIP backing as it votes to expand RSV vaccine recommendation

The U.S. Centers for Disease Control and Prevention’s vaccine panel voted to expand its recommendation for the use of respiratory syncytial virus (RSV) shots in adults with 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease, Pfizer (